

Neferine Datasheet

4th Edition (Revised in July, 2016)

[Product Information]

Name: Neferine

Catalog No.: CFN99581

Cas No.: 2292-16-2


Purity: >=98%

M.F: C₃₈H₄₄N₂O₆

M.W: 624.77

Physical Description: White powder

Synonyms: 4-[[[(1R)-6,7-Dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]methyl]-2-[[[(1R)-6-methoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-3,4-dihydro-1H-isoquinolin-7-yl]oxy]phenol.



[Intended Use]

1. Reference standards;
2. Pharmacological research;
3. Synthetic precursor compounds;
4. Intermediates & Fine Chemicals;
5. Others.

[Source]

The plantule of *Nelumbo nucifera* Gaertn.

[Biological Activity or Inhibitors]

Neferine shows significant improvement in cognitive impairment in scopolamine-induced amnesia animal models and moderate inhibitory activities in cholinesterases (ChEs) and beta-site APP cleaving enzyme 1 (BACE1) assays; it also exhibits notable scavenging activities against DPPH, ABTS, NO, and O(2)(-) radicals, as well as ONOO(-), it demonstrates remarkable inhibitory activity against lipid peroxidation and protein nitration in cell-free antioxidant assays and moderate inhibitory activity of NO generation with exceptional suppression of NF-kappaB activation in cell-based assays; suggests that the anti-amnesic effect of neferine may be mediated via antioxidant and anti-inflammatory capacities, as well as inhibition of ChEs and BACE1.^[1]

Neferine induces autophagy through the inhibition of PI3K/Akt/mTOR pathway and ROS hyper generation in A549 cells.^[2]

Neferine attenuates bleomycin-induced pulmonary fibrosis in vitro and in vivo, the beneficial effect of neferine may be associated with its activities of anti-inflammation, antioxidation, cytokine and NF-kappaB inhibition. ^[3]

Neferine has effects similar to rosiglitazone in decreasing fasting blood glucose, insulin, triglycerides (TG), tumor necrosis factor-alpha (TNF-alpha) and enhancing insulin sensitivity in insulin resistant rats.^[4]

Neferine inhibits proliferation of human osteosarcoma cells by promoting p38 MAPK-mediated p21 stabilization.^[5]

Neferine shows anti-anxiety effects and that neferine may participate in the efficacy of the sedative effects of embryos of the seeds of *Nelumbo nucifera*, the mechanisms of the sedative effects of neferine are not similar to those of diazepam.^[6]

Neferine possesses a significant inhibitory effect on amiodarone-induced pulmonary fibrosis, probably due to its properties of anti-inflammation, surfactant protein-D (SP-D) inhibition and restoring increased CD4+CD25+ Tregs which may modulate Th1/Th2 imbalance by suppressing Th2 response (from Th2 polarity toward a Th1 dominant response).^[7]

Neferine shows antidepressant-like effects in mice similar to typical antidepressants and

that these effects are mediated by the 5-HT 1A receptor, therefore, the central effects of neferine are likely to be linked to serotonergic neurotransmission.^[8]

Neferine exerts strong antioxidant property against isoproterenol-induced oxidative stress and can be used as a potent cardioprotective agent against isoproterenol-induced myocardial infarction.^[9]

[Solvent]

Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.

[HPLC Method]^[10]

Mobile phase: Methanol- 0.2 M KH₂PO₄- 0.2 M NaOH- Triethylamine= 71:17:12:0.002, (pH 9.2-9.3) ;

Flow rate: 0.8 ml/min;

Column temperature: Room Temperature;

The wave length of determination: 282 nm.

[Storage]

2-8°C, Protected from air and light, refrigerate or freeze.

[References]

- [1] Jung H A, Jin S R, Kim D H, *et al. Life Sci.*, 2010, 87(13-14):420-30.
- [2] Poornima P, Weng C F, Padma V V. *Food Chem.*, 2013, 141(4):3598-605.
- [3] Zhao L, Wang X, Chang Q, *et al. Eur. J. Pharmacol.*, 2010, 627(1-3):304-12.
- [4] Pan Y, Cai B, Wang K, *et al. J. Ethnopharmacol.*, 2009, 124(1):98-102.
- [5] Zhang X, Liu Z, Xu B, *et al. Eur. J. Pharmacol.*, 2012, 677(1-3):47-54.
- [6] Sugimoto Y, Furutani S, Itoh A, *et al. Phytomed. Int. J. Phytother. Phytopharmacol.*, 2008, 15(12):1117-24.
- [7] Niu C H, Wang Y, Liu J D, *et al. Eur.J. Pharmacol.*, 2013, 714(1-3):112-19.

[8] Sugimoto Y, Furutani S, Nishimura K, *et al. Eur. J. Pharmacol.*, 2010, 634(1–3):62-7.

[9] Lalitha G, Poornima P, Archanah A, *et al. Cardiovasc. Toxicol.*, 2013, 13(2):168-79.

[10] Huang Y, Zhao L, Bai Y, *et al. Arzneimittel-Forsch.*, 2011, 61(6):347-52.

[Contact]

Address:

S5-3 Building, No. 111, Dongfeng Rd.,
Wuhan Economic and Technological Development Zone,
Wuhan, Hubei 430056,
China

Email: info@chemfaces.com

Tel: +86-27-84237783

Fax: +86-27-84254680

Web: www.chemfaces.com

Tech Support: service@chemfaces.com